Hepatotoxicity Risk Assessment of Long-Term Non-Steroidal Anti-Inflammatory Drug Use: A Retrospective Cohort Study
DOI:
https://doi.org/10.5281/zenodo.22664429Keywords:
NSAID hepatotoxicity, drug-induced liver injury, diclofenac, idiosyncratic liver injury, pharmacovigilanceAbstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications for acute and chronic
pain, yet their hepatotoxic potential during long-term use has received comparatively less sustained clinical attention than their
gastrointestinal, renal, and cardiovascular risks. Objective: This review synthesizes the published cohort, case-control, prospective
drug-induced liver injury (DILI) registry, and mechanistic literature on hepatotoxicity associated with long-term NSAID use, with
attention to incidence, risk factors, injury mechanisms, and monitoring recommendations. Methods: A narrative review was
conducted using targeted searches of PubMed/MEDLINE and Crossref-indexed journals; each candidate reference was individually
verified against its publisher or bibliographic database record before inclusion, and sources were organized thematically into
population-based epidemiology, mechanisms, comparative agent-specific risk, and clinical monitoring guidance. Findings: Regular
NSAID users show a consistently elevated relative risk of acute liver injury compared with non-users across multiple independent
pharmacoepidemiological and registry-based data sources, although absolute incidence remains low. Hepatotoxicity is
overwhelmingly idiosyncratic rather than dose-predictable and varies substantially by agent: diclofenac and nimesulide carry the
strongest and most consistently documented hepatotoxicity signal, attributable to reactive metabolite formation and
mitochondrial toxicity respectively, while ibuprofen, naproxen, and celecoxib appear comparatively safer. Genetic susceptibility,
advanced age, pre-existing liver disease, and hepatotoxic co-medication modify individual risk. Current American and European
guidelines favor risk-stratified vigilance over universal biochemical surveillance, given the poor predictive value of routine
monitoring for idiosyncratic injury. Conclusions: Long-term NSAID use carries a small but consistent hepatotoxicity risk that differs
meaningfully by individual agent. Prescribing choices informed by agent-specific risk profiles, patient education on warning
symptoms, and continued investment in DILI pharmacovigilance registries represent the most promising strategies for reducing
this uncommon but serious adverse effect.
References
Aithal GP, Day CP (2007) Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clinics in Liver Disease, 11(3):563-575, DOI:10.1016/j.cld.2007.06.004.
Bessone F (2010) Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World Journal of Gastroenterology, 16(45):5651-5661, DOI:10.3748/wjg.v16.i45.5651.
Boelsterli UA (2002) Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Safety, 25(9):633-648, DOI:10.2165/00002018-200225090-00003.
Garcia Rodriguez LA, Williams R, Derby LE, Dean AD, Jick H (1994) Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Archives of Internal Medicine, 154(3):311-316, DOI:10.1001/archinte.1994.00420030117012.
Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M (2003) Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ, 327(7405):18-22, DOI:10.1136/bmj.327.7405.18.
Schmeltzer PA, Kosinski AS, Kleiner DE, Hoofnagle JH, Stolz A, Fontana RJ, Russo MW (2016) Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver International, 36(4):603-609, DOI:10.1111/liv.13032.
Bonkovsky HL, Ghabril M, Nicoletti P, Dellinger A, Fontana RJ, Barnhart H, Gu J, Daly AK, Aithal GP, Phillips EJ, Kleiner DE (2024) Drug-induced liver injury (DILI) ascribed to non-steroidal anti-inflammatory drugs (NSAIDs) in the USA-Update with genetic correlations. Liver International, 44(6):1409-1421, DOI:10.1111/liv.15892.
Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S (2013) Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology, 144(7):1419-1425, DOI:10.1053/j.gastro.2013.02.006.
Kwon J, Kim S, Yoo H, Lee E (2019) Nimesulide-induced hepatotoxicity: a systematic review and meta-analysis. PLOS ONE, 14(1):e0209264, DOI:10.1371/journal.pone.0209264.
Sriuttha P, Sirichanchuen B, Permsuwan U (2018) Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. International Journal of Hepatology, 2018:5253623, DOI:10.1155/2018/5253623.
Rostom A, Goldkind L, Laine L (2005) Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clinical Gastroenterology and Hepatology, 3(5):489-498, DOI:10.1016/S1542-3565(04)00777-3.
Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, Gatta A, McCormick PA, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Benichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N (2013) Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Safety, 36(2):135-144, DOI:10.1007/s40264-012-0013-7.
Boelsterli UA (2003) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicology and Applied Pharmacology, 192(3):307-322, DOI:10.1016/S0041-008X(03)00368-5.
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK (2011) Case definition and phenotype standardization in drug-induced liver injury. Clinical Pharmacology & Therapeutics, 89(6):806-815, DOI:10.1038/clpt.2011.58.
Zoubek ME, Lucena MI, Andrade RJ, Stephens C (2020) Systematic review: ibuprofen-induced liver injury. Alimentary Pharmacology & Therapeutics, 51(6):603-611, DOI:10.1111/apt.15645.
Banks AT, Zimmerman HJ, Ishak KG, Harter JG (1995) Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology, 22(3):820-827, DOI:10.1002/hep.1840220320.
Zoubek ME, Gonzalez-Jimenez A, Medina-Caliz I, Robles-Diaz M, Hernandez N, Romero-Gomez M, Bessone F, Hallal H, Cubero FJ, Lucena MI, Stephens C, Andrade RJ (2018) High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. Clinical Gastroenterology and Hepatology, 16(2):292-294, DOI:10.1016/j.cgh.2017.07.037.
Bessone F, Hernandez N, Roma MG, Ridruejo E, Mendizabal M, Medina-Caliz I, Robles-Diaz M, Lucena MI, Andrade RJ (2016) Hepatotoxicity induced by coxibs: how concerned should we be? Expert Opinion on Drug Safety, 15(11):1463-1475, DOI:10.1080/14740338.2016.1225719.
Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR (2021) ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. American Journal of Gastroenterology, 116(5):878-898, DOI:10.14309/ajg.0000000000001259.
Danan G, Teschke R (2016) RUCAM in Drug and Herb Induced Liver Injury: The Update. International Journal of Molecular Sciences, 17(1):14, DOI:10.3390/ijms17010014.
Andrade RJ, Aithal GP, Bjornsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, Karlsen TH (2019) EASL Clinical Practice Guidelines: Drug-induced liver injury. Journal of Hepatology, 70(6):1222-1261, DOI:10.1016/j.jhep.2019.02.014.
